Poly Medicure has announced the acquisition of the Citieffe Group, its second acquisition in September. The acquisition is part of Poly Medicure inorganic growth strategy, which focuses on acquiring high-technology companies that provide access to key markets like Europe and the US. The acquisition of Citieffe provides a platform for PLM to expand into the orthopedics segment, specifically focusing on the fastgrowing trauma and extremities sub-segment.
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Report
Poly Medicure Ltd. has announced acquisition of the Citieffe Group (Euro 31 million, at 10 times Ebitda) which is an Italy based medical device manufacturer focused on the fast-growing trauma and extremities sub-segment in the orthopedics space. This is the second acquisition by Poly Medicure in recent past and in line with their strategy to build presence in high value categories in medical device space inorganically.
We understand the acquisition has been done with a long term view. It adds niche capabilities to Poly Medicure and helps them enter a space with meaningful entry barriers and with a large growth potential.
The contribution margin of acquired business is high (~90%) and as they scale up we will see operating leverage kicking in meaningfully. There is enough spare capacity for Citieffe to scale up meaningfully higher from current levels without any incremental meaningful investments. Foray into plates manufacturing (expected in the near term) will meaningfully expand the target addressable market for Citieffe.
There are global players already entrenched in the category and hence Poly Medicure will need to find ways to differentiate to accelerate growth for themselves.
We retain our Rating to Hold and Target Price to Rs 2,016 with a multiple of 45 times on FY27 EPS.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
